157 related articles for article (PubMed ID: 38584178)
1. Spectrally separated dual-label upconversion luminescence lateral flow assay for cancer-specific STn-glycosylation in CA125 and CA15-3.
Ekman M; Salminen T; Raiko K; Soukka T; Gidwani K; Martiskainen I
Anal Bioanal Chem; 2024 May; 416(13):3251-3260. PubMed ID: 38584178
[TBL] [Abstract][Full Text] [Related]
2. Europium Nanoparticle-Based Sialyl-Tn Monoclonal Antibody Discriminates Epithelial Ovarian Cancer-Associated CA125 from Benign Sources.
Gidwani K; Nadeem N; Huhtinen K; Kekki H; Heinosalo T; Hynninen J; Perheentupa A; Poutanen M; Carpen O; Pettersson K; Lamminmäki U
J Appl Lab Med; 2019 Nov; 4(3):299-310. PubMed ID: 31659068
[TBL] [Abstract][Full Text] [Related]
3. Diagnostic potential of nanoparticle aided assays for MUC16 and MUC1 glycovariants in ovarian cancer.
Jain S; Nadeem N; Ulfenborg B; Mäkelä M; Ruma SA; Terävä J; Huhtinen K; Leivo J; Kristjansdottir B; Pettersson K; Sundfeldt K; Gidwani K
Int J Cancer; 2022 Oct; 151(7):1175-1184. PubMed ID: 35531590
[TBL] [Abstract][Full Text] [Related]
4. Nanoparticle-aided glycovariant assays to bridge biomarker performance and ctDNA results.
Gidwani K; Kekki H; Terävä J; Soukka T; Sundfeldt K; Pettersson K
Mol Aspects Med; 2020 Apr; 72():100831. PubMed ID: 31787337
[TBL] [Abstract][Full Text] [Related]
5. Exploratory Analysis of CA125-MGL and -STn Glycoforms in the Differential Diagnostics of Pelvic Masses.
Salminen L; Nadeem N; Rolfsen AL; Dørum A; Laajala TD; Grènman S; Hietanen S; Heinosalo T; Perheentupa A; Poutanen M; Bolstad N; Carpén O; Lamminmäki U; Pettersson K; Gidwani K; Hynninen J; Huhtinen K
J Appl Lab Med; 2020 Mar; 5(2):263-272. PubMed ID: 32445385
[TBL] [Abstract][Full Text] [Related]
6. A Nanoparticle-Lectin Immunoassay Improves Discrimination of Serum CA125 from Malignant and Benign Sources.
Gidwani K; Huhtinen K; Kekki H; van Vliet S; Hynninen J; Koivuviita N; Perheentupa A; Poutanen M; Auranen A; Grenman S; Lamminmäki U; Carpen O; van Kooyk Y; Pettersson K
Clin Chem; 2016 Oct; 62(10):1390-400. PubMed ID: 27540033
[TBL] [Abstract][Full Text] [Related]
7. Diagnostic measures comparison for ovarian malignancy risk in Epithelial ovarian cancer patients: a meta-analysis.
Suri A; Perumal V; Ammalli P; Suryan V; Bansal SK
Sci Rep; 2021 Aug; 11(1):17308. PubMed ID: 34453074
[TBL] [Abstract][Full Text] [Related]
8. Glycovariant-based lateral flow immunoassay to detect ovarian cancer-associated serum CA125.
Bayoumy S; Hyytiä H; Leivo J; Talha SM; Huhtinen K; Poutanen M; Hynninen J; Perheentupa A; Lamminmäki U; Gidwani K; Pettersson K
Commun Biol; 2020 Aug; 3(1):460. PubMed ID: 32826955
[TBL] [Abstract][Full Text] [Related]
9. Microarray Glycoprofiling of CA125 improves differential diagnosis of ovarian cancer.
Chen K; Gentry-Maharaj A; Burnell M; Steentoft C; Marcos-Silva L; Mandel U; Jacobs I; Dawnay A; Menon U; Blixt O
J Proteome Res; 2013 Mar; 12(3):1408-18. PubMed ID: 23360124
[TBL] [Abstract][Full Text] [Related]
10. Aberrant glycosylation of α3 integrins as diagnostic markers in epithelial ovarian cancer.
Jain S; Parimelazhagan Santhi P; Vinod R; Afrin Ruma S; Huhtinen K; Pettersson K; Sundfeldt K; Leivo J; Gidwani K
Clin Chim Acta; 2023 Mar; 543():117323. PubMed ID: 37003518
[TBL] [Abstract][Full Text] [Related]
11. Microchip fluorescence-enhanced immunoaasay for simultaneous quantification of multiple tumor markers.
Shi M; Zhao S; Huang Y; Liu YM; Ye F
J Chromatogr B Analyt Technol Biomed Life Sci; 2011 Sep; 879(26):2840-4. PubMed ID: 21873123
[TBL] [Abstract][Full Text] [Related]
12. Pre-operative discrimination between benign and malignant ovarian tumors using a combination of CA125 and CA15.3 serum assays.
Yedema C; Massuger L; Hilgers J; Servaas J; Poels L; Thomas C; Kenemans P
Int J Cancer Suppl; 1988; 3():61-7. PubMed ID: 3209301
[TBL] [Abstract][Full Text] [Related]
13. Anti-CA15.3 and Anti-CA125 Antibodies and Ovarian Cancer Risk: Results from the EPIC Cohort.
Cramer DW; Fichorova RN; Terry KL; Yamamoto H; Vitonis AF; Ardanaz E; Aune D; Boeing H; Brändstedt J; Boutron-Ruault MC; Chirlaque MD; Dorronsoro M; Dossus L; Duell EJ; Gram IT; Gunter M; Hansen L; Idahl A; Johnson T; Khaw KT; Krogh V; Kvaskoff M; Mattiello A; Matullo G; Merritt MA; Nodin B; Orfanos P; Onland-Moret NC; Palli D; Peppa E; Quirós JR; Sánchez-Perez MJ; Severi G; Tjønneland A; Travis RC; Trichopoulou A; Tumino R; Weiderpass E; Fortner RT; Kaaks R
Cancer Epidemiol Biomarkers Prev; 2018 Jul; 27(7):790-804. PubMed ID: 29661801
[No Abstract] [Full Text] [Related]
14. Nipple discharge of CA15-3, CA125, CEA and TSGF as a new biomarker panel for breast cancer.
Wang G; Qin Y; Zhang J; Zhao J; Liang Y; Zhang Z; Qin M; Sun Y
Int J Mol Sci; 2014 May; 15(6):9546-65. PubMed ID: 24879526
[TBL] [Abstract][Full Text] [Related]
15. Preoperative determination of several serum tumor markers in patients with primary epithelial ovarian carcinoma.
Kudoh K; Kikuchi Y; Kita T; Tode T; Takano M; Hirata J; Mano Y; Yamamoto K; Nagata I
Gynecol Obstet Invest; 1999; 47(1):52-7. PubMed ID: 9852392
[TBL] [Abstract][Full Text] [Related]
16. Puerperal mastitis: a reproductive event of importance affecting anti-mucin antibody levels and ovarian cancer risk.
Cramer DW; Williams K; Vitonis AF; Yamamoto HS; Stuebe A; Welch WR; Titus L; Fichorova RN
Cancer Causes Control; 2013 Nov; 24(11):1911-23. PubMed ID: 23925696
[TBL] [Abstract][Full Text] [Related]
17. Evaluation of two new assays for tumor-associated antigens, CASA and OSA, found in the serum of patients with epithelial ovarian carcinoma--comparison with CA125.
McGuckin MA; Layton GT; Bailey MJ; Hurst T; Khoo SK; Ward BG
Gynecol Oncol; 1990 May; 37(2):165-71. PubMed ID: 1693126
[TBL] [Abstract][Full Text] [Related]
18. Different levels of sialyl-Tn antigen expressed on MUC16 in patients with endometriosis and ovarian cancer.
Akita K; Yoshida S; Ikehara Y; Shirakawa S; Toda M; Inoue M; Kitawaki J; Nakanishi H; Narimatsu H; Nakada H
Int J Gynecol Cancer; 2012 May; 22(4):531-8. PubMed ID: 22367369
[TBL] [Abstract][Full Text] [Related]
19. Clinical significance of combined detection of serum tumor markers in diagnosis of patients with ovarian cancer.
Bian J; Li B; Kou XJ; Liu TZ; Ming L
Asian Pac J Cancer Prev; 2013; 14(11):6241-3. PubMed ID: 24377511
[TBL] [Abstract][Full Text] [Related]
20. A multiplex biomarker assay improves the diagnostic performance of HE4 and CA125 in ovarian tumor patients.
Leandersson P; Åkesson A; Hedenfalk I; Malander S; Borgfeldt C
PLoS One; 2020; 15(10):e0240418. PubMed ID: 33075095
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]